Bug Bite Thing partnership with certified pediatrician Dr. Mona Amin

Dr. Mona frequently treats children experiencing localized reactions from insect bites and stings.

Novartis Tafinlar and Mekinist demonstrates unprecedented efficacy in pediatric patients

If approved, Tafinlar + Mekinist may offer a potential new standard-of-care for pediatric patients with this brain cancer

Pfizer initiates Phase2/3 study of Paxlovid in pediatric participants

Paxlovid is the first oral therapy specifically designed to combat Covid-19 to be evaluated in a pediatric clinical study

Lantern Pharma collaborates with GCCRI for pediatric cancer

Dr. Peter Houghton will lead the research collaboration for GCCRI and is widely regarded as a leading expert in pediatric cancer research and in the development of novel approaches to treating childhood cancers

Novartis secures new approval in China for Cosentyx in pediatric psoriasis

Cosentyx is a proven treatment, supported by long-term five-year sustained efficacy and safety data across several inflammatory conditions and with more than 500,000 patients treated worldwide since launch

Biocon Biologics secures Health Canada nod for biosimilars Yesintek, Yesintek IV

Yesintek and Yesintek I.V. are approved for the treatment of moderate to severe plaque psoriasis in adults and pediatric patients

FDA approves Tezspire for chronic rhinosinusitis with nasal polyps

Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation

Biocon Biologics and Civica launch private-label Insulin glargine

Lupin to build $250 million manufacturing facility in Florida

Furthering?U.S.-based?pharmaceutical?capacity?to?produce?critical respiratory medicines?

Health Secretary Srivastava chairs meeting with states/UTs on quality and rational use of cough syrups

States exhorted to ensure rational use of cough syrups, particularly among children, as most coughs are self-limiting and do not require pharmacological treatment